
By Stine Jacobsen and Maggie Fick
COPENHAGEN, March 26 (Reuters) - Novo Nordisk has appointed Poul Weihrauch, CEO of U.S. candy giant Mars, as board observer as the drugmaker seeks to strengthen its position in the highly competitive U.S. obesity market.
The maker of weight-loss drug Wegovy announced the appointment at Thursday's annual general meeting, where shareholders also elected pharmaceutical veterans Jan van de Winkel and Ramona Sequeira to the board, along with Helena Saxon, a board member at fashion retailer H&M.
Novo Nordisk and its majority shareholder, the Novo Nordisk Foundation, carried out a leadership shake-up last year, replacing the CEO and restructuring the board. This included the consolidation of Lars Rebien Sorensen's leadership role through his appointment as board chairman in addition to his role of chairman of the foundation.
NOVO AIMS TO BOOST CONSUMER CREDENTIALS
Sorensen has promised to strengthen the board's pharmaceutical and commercial expertise after criticising the previous board for being slow to address U.S. market challenges.
Novo is trying to boost consumer credentials in the U.S. market in a number of ways under its new management. In January it launched its Wegovy pill across multiple cash-pay channels, rather than solely through traditional insurance routes.
The company is leaning into telehealth, retail partnerships and direct-to-consumer access, as well as cutting prices under pressure from the Trump administration and to win cash-pay patients. Novo and chief rival Eli Lilly and Co have said the obesity market is becoming increasingly consumer-driven.
"We need to start to see our community more as customers than as patients," Sorensen told reporters after Thursday's meeting, adding that it was studying consumer behaviour to better understand what drives people to seek treatment, where they prefer to access it and when they are most likely to buy.
Sorensen said that Novo had looked at over-the-counter medicines for insight but added that companies in fast-moving consumer goods may provide a closer comparison because of their expertise in tracking purchasing habits and identifying unmet demand.
Those kinds of consumer insights could improve how Novo addresses the needs of overweight people and identify where GLP-1 drugs or other treatments might fit, Sorensen said.
Asked about the apparent contradictions in the appointment of a confectionery company executive by a manufacturer of obesity drugs, Sorensen said both types of companies are highly sophisticated in understanding customers and their needs.
(Reporting by Stine Jacobsen and Maggie FickEditing by Anna Ringstrom, Barbara Lewis and David Goodman)
latest_posts
- 1
'The Beast in Me' arrives on Netflix: Is it based on a true story? And what drew Claire Danes to it? What to know about the thriller series. - 2
The Ursid meteor shower will be the last of the year, peaking just before Christmas: What to know and how to watch - 3
Behind every perfect holiday memory is a mom on the brink - 4
New movies to watch this week: See 'Marty Supreme' in theaters, rent 'Springsteen: Deliver Me from Nowhere,' stream 'Cover-Up' on Netflix - 5
How to watch Dick Clark’s New Year’s Rockin’ Eve with Ryan Seacrest: Start time, TV channel, performers and more
Seoul says sorry after unapproved drone flights into North Korea
Vote in favor of your #1 Kind of Cap
Instructions to Pick the Best Course for Your Next Waterway Voyage: Objections, Views, and Social Encounters
Several killed in Ukraine and Russia after cross-border attacks
Manual for Tracking down the Immaculate Magnificence of Focal Asia
Ads promising cosmetic surgery patients a ‘dream body’ with minimal risk get little scrutiny
China Just Got A Lot Closer To Its First-Ever Manned Moon Landing
Alleged Huione Group Money Laundering Boss Extradited to China
Polish law aimed at lowering petrol prices takes effect on Tuesday









